0001437749-23-031996.txt : 20231114 0001437749-23-031996.hdr.sgml : 20231114 20231114162547 ACCESSION NUMBER: 0001437749-23-031996 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231114 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231114 DATE AS OF CHANGE: 20231114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Perspective Therapeutics, Inc. CENTRAL INDEX KEY: 0000728387 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 411458152 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33407 FILM NUMBER: 231406833 BUSINESS ADDRESS: STREET 1: 2401 ELLIOTT AVENUE STREET 2: SUITE 320 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: (509) 375-1202 MAIL ADDRESS: STREET 1: 2401 ELLIOTT AVENUE STREET 2: SUITE 320 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: Isoray, Inc. DATE OF NAME CHANGE: 20181231 FORMER COMPANY: FORMER CONFORMED NAME: IsoRay, Inc. DATE OF NAME CHANGE: 20050805 FORMER COMPANY: FORMER CONFORMED NAME: CENTURY PARK PICTURES CORP DATE OF NAME CHANGE: 19920703 8-K 1 isr20231113_8k.htm FORM 8-K isr20230512_8k.htm
false 0000728387 0000728387 2023-11-14 2023-11-14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): November 14, 2023
 
Perspective Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
 
Delaware
(State or Other Jurisdiction
of Incorporation)
001-33407
(Commission
File Number)
41-1458152
(IRS Employer
Identification No.)
 
2401 Elliott Avenue, Suite 320, Seattle, Washington 98121
(Address of Principal Executive Offices) (Zip Code)
 
(509) 375-1202
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
CATX
NYSE American
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 2.02
 Results of Operations and Financial Condition.
 
On November 14, 2023, Perspective Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023 and providing recent business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02.
 
The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.
 
Item 9.01
Financial Statements and Exhibits.
 
 
(d)
Exhibits.
 
 
99.1
 Press release issued by Perspective Therapeutics, Inc., dated November 14, 2023.
 
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: November 14, 2023
 
Perspective Therapeutics, Inc.
 
 
By: /s/ Johan (Thijs) Spoor  
 
Johan (Thijs) Spoor
Chief Executive Officer
  
 
 
 
 
 EX-99.1 2 ex_597074.htm EXHIBIT 99.1 ex_597074.htm

Exhibit 99.1

 

ex_597074img001.jpg

 

 

 

Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights

 

SEATTLE – November 14, 2023 – Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced third quarter financial results for the period ended September 30, 2023 and provided recent business highlights. 

 

“Our commitment to advancing targeted alpha-particle therapies against neuroendocrine tumors remains steadfast as we have completed dosing of the first patient in the Phase 1/2a clinical trial of [212Pb]VMT-α-NET,” said Thijs Spoor, Perspective Therapeutics' CEO. “In addition, we completed recruitment for the first patient cohort in the Company-sponsored Phase 1/2a dose escalation/dose expansion clinical trial evaluating [212Pb]VMT01 for the treatment of histologically confirmed melanoma. We are nearing completion of the imaging portion of the clinical trial evaluating the suitability of [203Pb]VMT01 for SPECT/CT imaging.”

 

“We are pleased with our execution this quarter and continue to see positive momentum in the number of patients being treated with Cesium-131 each month, marking a return to growth as compared to the same period in the prior year,” stated Andrew Bright, Perspective Therapeutics’ Executive Vice President of Brachytherapy. “The rebound in the number of patients treated was driven by engagement with current customers, as well as new customers adopting Cesium-131 in their brachytherapy programs. Additionally, increased utilization of Cesium-131 is evident in our core prostate business, as well as in other disease areas, notably lung and brain brachytherapy.”

 

VMT-α-NET Recent Highlights 

 

Company-sponsored Phase 1/2a clinical trial of [212Pb]VMT-α-NET

 

●

Dosed first patient in the Phase 1/2a clinical trial of [212Pb]VMT-α-NET for unresectable or metastatic SSTR2-expressing neuroendocrine tumors (NETs) at Washington University in St. Louis.

 

●

The Company currently has two active sites for the clinical trial and anticipates that two additional clinical trial sites will become operational in December.

 

 
 

 

●

The Company remains on track to launch an additional 14 clinical trial sites.

 

Investigator-Initiated clinical trials of [212Pb]VMT-α-NET

 

●

Presented early clinical findings at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) for the Phase 2a clinical trial of [212Pb]VMT-α-NET in pre- and post-Lutathera gastroenteropancreatic (GEP)-NET patients, being conducted at Fortis Healthcare, India. Dr. Dharmender Malik of Fortis Memorial Research Institute presented data on [212Pb]VMT-α-NET therapy in 10 patients who had failed prior treatment, including standard care. Initial data readout demonstrated high objective response rate for 7 of 9 evaluable patients, spanning peptide receptor radionuclide therapy (PRRT)-naïve and PRRT-refractory cases. Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients. All ongoing patients are expected to complete their 4th treatment cycle by the end of February 2024. Updated clinical results are expected to be presented at an upcoming scientific meeting in 2024.

 

●

Two patients were screened in the Phase 1/2a clinical trial for post-Lutathera GEP-NET patients at the University of Iowa. A third patient is scheduled for screening mid-November. If eligible, all three patients will receive treatment in December for the completion of the first cohort. The end of fourth cycle of treatment is expected in June 2024.

 

●

End-of-life compassionate use program for patients with advanced NETs and lack of further treatment options is underway at the University Dresden in Germany. Four patients were treated during the third quarter, and investigators are planning additional treatments before the end of the year.

 

●

IND submissions are expected in November with subsequent trial activation in the first half of 2024 for NIH-sponsored studies in pre- and post-Lutathera NET patients.

 

VMT01 Recent Highlights

 

 

●

Completed recruitment for the first patient cohort in the Company-sponsored Phase 1/2a dose escalation/dose expansion clinical trial of [212Pb]VMT01 in patients with histologically confirmed melanoma and positive MC1R imaging scans. Three patients have been dosed at 111 MBq (3mCi), closing cohort 1. No serious adverse events or dose-limiting toxicities have been observed. The Company anticipates opening the second patient cohort, which will receive 185 MBq (5mCi) per dose, in December 2023 and anticipates the completion of screening in the first quarter of 2024.

 

 

●

Nearing completion of analysis of the dosimetry portion of the Company’s TIMAR-1 clinical trial, a first-in-human study evaluating the suitability of [203Pb]VMT01 for SPECT/CT imaging and [68Ga]VMT02 for PET/CT imaging of MC1R-expressing metastatic melanoma. Perspective is actively working on the Clinical Study Report and anticipates it will be released in the first half of 2024.

 

 
 

 

Brachytherapy Recent Highlights

 

●

Third quarter 2023 revenue was the highest since the second quarter of 2022, with a return to growth over the third quarter of 2022.

 

●

Appointed sales, marketing and clinical team members along with a senior customer service representative to supplement Perspective’s dedicated commercial team.

 

●

Launched marketing initiatives to increase direct patient communication and engagement on Cesium-131 brachytherapy.

 

●

Facilitated timely access to GT Medical’s GammaTile for challenging brain cancers through increased production of Cesium-131 brachytherapy seeds that allowed GT Medical to address short notice orders with increased confidence.

 

●

Presented long-term data for Cesium-131 brachytherapy in the treatment of prostate cancer at the American Society for Radiation Oncology (ASTRO) annual conference. In his presentation, Dr. Mohamed Abdelhakiem of the UPMC Hillman Cancer Center described urinary data collected from 341 patients treated with Cesium-131 between 2006 and 2022.

 

●

Presented preliminary long-term data for Cesium-131 utilized in salvage treatment of recurrent cervical and uterine cancers at the ASTRO annual conference. Dr. Zeta Chow of the University of Kentucky showed data that indicated Cesium-131 brachytherapy is a promising alternative to pelvic exenteration, a significant surgical procedure.

 

●

Publication of peer reviewed article in the journal of Brachytherapy highlighting Cesium-131 clinical data from Dr. Benoit and colleagues at the University of Pittsburgh School of Medicine. The results support Cesium-131 and provide additional data on dose parameters for improved urinary side effect profile without affecting disease free survival. [https://www.brachyjournal.com/article/S1538-4721(23)01632-X/fulltext]

 

Discovery Program Milestones 

 

●

Presented data at EANM. Dijie Liu, Principal Research Scientist at Perspective, presented mouse model data highlighting the efficacy of [203/212Pb]VMT-α-NET in treating metastatic neuroblastoma tumors. The study showed successful tumor uptake via sequential SPECT imaging and demonstrated a maximum tolerated dose of [212Pb]VMT-α-NET as 2.22 MBq without acute toxicity, with a 100% overall survival rate at 90-days observed in the group receiving three fractionated doses of 740 kBq of [212Pb]VMT-α-NET.

 

●

Presented collaborative data at the World Molecular Imaging Congress. Dr. Michael K. Schultz, Chief Science Officer of Perspective presented data highlighting the effectiveness of [212Pb]VMT-α-NET in treating neuroendocrine tumors in a tumor xenograft mouse model. The results highlighted the significant therapeutic efficacy of treatment with three fractionated doses of [212Pb]VMT-α-NET, which resulted in a 70% complete response rate and 80% survival at 120 days.

 

 
 

 

 

●

Presented encouraging data on novel guest/host platform for effective in vivo image-guided pre-targeted alpha particle therapy at the World Molecular Imaging Congress. Dr. Amritjyot Kaur of Stony Brook University showed that the radioligand [203Pb]PSC-PEG3-Adma demonstrated extended lag times, impressive tumor-to-tissue ratios and has the potential to further reduce radiation toxicity using [203Pb]PSC-PEG3-Adma as a guide.

 

●

Publication of a peer-reviewed article in Nuclear Medicine and Biology reporting on collaborative research with the University of Alberta, to accelerate the availability of imaging surrogate isotope Pb-203 for image-guided dosimetry planning of Pb-212 labeled radiopeptide conjugates. The collaboration has established an approach to production that can be readily adopted by other cyclotron facilities that produce high yields and excellent specific activity. [https://pubmed.ncbi.nlm.nih.gov/36708660/]

 

Third Quarter 2023 Financial Summary 

 

Total revenue for the three months ended September 30, 2023 was $2.19 million, compared to $1.72 million for the same period in 2022, an increase of 27%. 

 

●

Sales revenues for the quarter ended September 30, 2023, was $1.9 million, compared to $1.7 million for the same period in 2022, an increase of 11%.

 

●

Prostate brachytherapy represented 55% of total revenue for the quarter ended September 30, 2023 compared to 68% for the same period in 2022.

 

Gross profit was $738,000 for the three months ended September 30, 2023 compared to $414,000 for the same period in 2022. 

 

Research and development expenses were $5.7 million for the three months ended September 30, 2023 compared to $708,000 for the same period in 2022, an increase of 708%. Management continues to believe that research and development expenses may increase as the Company continues to advance its clinical programs. 

 

Total operating expenses for the quarter ended September 30, 2023 were $11.3 million, compared to $4.6 million for the same period in 2022, an increase of 144%.

 

Net loss for the three months ended September 30, 2023 was $10.4 million or $0.04 per share basic and diluted, compared to $4.1 million or $0.03 per share basic and diluted for the same period in 2022. 

 

 
 

 

Cash and cash equivalents as of September 30, 2023, was $18.0 million as compared to $43.9 million on December 31, 2022. Based on the Company’s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into late second quarter of 2024.

 

About Perspective Therapeutics, Inc. 

Perspective Therapeutics, Inc., is a diversified medical technology and radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope Lead-212 to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. 

 

The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions in the United States. The Company has also developed a proprietary Lead-212 generator to secure key isotopes for clinical trial and commercial operations.

 

In addition to its targeted alpha therapy programs, Perspective is the sole producer of Cesium-131 brachytherapy seeds which is commercially available in the United States for the treatment of prostate cancer and other solid tumors.

 

For more information, please visit the Company's website at www.perspectivetherapeutics.com. 

 

 
 

 

Safe Harbor Statement 

 

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential" or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things: the Company’s belief regarding the sufficiency of its cash resources to fund its operating expenses and capital expenditure requirements; the Company's clinical development plans and the expected timing thereof; the expected timing for availability and release of data; the Company’s timing and expectations regarding regulatory communications, submissions and approvals; expectations regarding the potential market opportunities for the Company's product candidates; the potential functionality, capabilities, and benefits of the Company's product candidates and the potential application of these product candidates for other disease indications; the Company's expectations, beliefs, intentions, and strategies regarding the future; the Company's expectations regarding the addition of clinical trial sites; the Company’s belief that research and development expenses may increase as the Company continues to advance its clinical programs; the Company's expectations regarding potential competitors; the Company's plans for bolstering sales efforts; the Company's expectations the impact of changes in reimbursement amounts for its products; and other statements that are not historical fact.

 

The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the potential that regulatory authorities may not grant or may delay approval for the Company's product candidates; uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; the Company’s ability to continue as a going concern; early clinical trials may not be indicative of the results in later clinical trials; clinical trial results may not support regulatory approval or further development in a specified indication or at all; actions or advice of regulatory authorities may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; the Company's ability to obtain and maintain regulatory approval for the Company's product candidates; delays, interruptions or failures in the manufacture and supply of the Company's product candidates; the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the Company's expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company's ability to obtain additional funding to support its clinical development programs; the availability or potential availability of alternative products or treatments for conditions targeted by the Company that could affect the availability or commercial potential of its product candidates; the ability of the Company to manage growth and successfully integrate its businesses; the Company's ability to maintain its key employees; whether there is sufficient training and use of the Company's products and product candidates; the market acceptance and recognition of the Company's products and product candidates; the Company's ability to maintain and enforce its intellectual property rights; the Company's ability to maintain its therapeutic isotope supply agreement with the Department of Energy; the Company's ability to continue to comply with the procedures and regulatory requirements mandated by the FDA for additional trials, Phase 1 and 2 approvals, Fast Track approvals, and 510(k) approval and reimbursement codes; and any changes in applicable laws and regulations. Other factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Transition Report on Form 10-KT and the Company's most recent Quarterly Report on Form 10-Q, each filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov.

Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.

 

 
 

 

Perspective Therapeutics, Inc. and Subsidiaries 

Condensed Consolidated Balance Sheets  (Unaudited)

(In thousands, except shares) 

 

   

September 30,

   

December 31,

 
   

2023

    

2022

  

ASSETS

               

Current assets:

                

Cash and cash equivalents

   $ 17,983     $ 20,993  

Short-term investments

     -       22,764  

Accounts receivable, net

     1,731       1,363  

Inventory

     1,013       1,409  

Note receivable

     -       6,109  

Prepaid expenses and other current assets

     961       577  
                 

Total current assets

     21,688       53,215  
                 

Property and equipment, net

     7,012       1,684  

Right of use asset, net

     1,529       378  

Restricted cash

     182       182  

Inventory, non-current

     2,237       2,396  

Intangible assets

     50,000       -  

Goodwill

     27,319       -  

Other assets, net

     551       236  
                 

Total assets

   $ 110,518     $ 58,091  
                 

LIABILITIES AND STOCKHOLDERS' EQUITY

               
                 

Current liabilities:

                

Accounts payable and accrued expenses

   $ 3,867     $ 1,541  

Lease liability

     293       276  

Accrued protocol expense

     311       233  

Accrued radioactive waste disposal

     24       129  

Accrued payroll and related taxes

     3,024       212  

Accrued vacation

     548       285  

Note payable, current

     48       -  
                 

Total current liabilities

     8,115       2,676  

Non-current liabilities:

                

Lease liability, non-current

     1,276       116  

Note payable

     1,689       -  

Asset retirement obligation

     668       657  
                 

Total liabilities

     11,748       3,449  

Commitments and contingencies

                
                 

Stockholders' equity:

                

Preferred stock, $.001 par value; 7,000,000 shares authorized: Series B: 5,000,000 shares allocated; no shares issued and outstanding

     -       -  

Common stock, $.001 par value; 750,000,000 shares authorized; 280,571,026 and 142,112,766 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively

     281       142  

Additional paid-in capital

     226,254       160,432  

Accumulated deficit

     (127,765

)

     (105,932

)
                 

Total stockholders' equity

     98,770       54,642  
                 

Total liabilities and stockholders' equity

   $ 110,518     $ 58,091  

 

 
 

 

Perspective Therapeutics, Inc. and Subsidiaries 

Condensed Consolidated Statements of Operations (Unaudited) 

(Dollars and shares in thousands, except for per-share amounts) 

 

   

Three months ended

    

Nine months ended

  
   

September 30,

   

September 30,

 
   

2023

    

2022

    

2023

    

2022

  
                                 

Sales, net

   $ 1,909     $ 1,717     $ 5,239     $ 7,132  

Grant revenue

     276       -       1,097       -  

Total revenue

     2,185       1,717       6,336       7,132  

Cost of sales

     1,447       1,303       4,863       4,351  

Gross profit

     738       414       1,473       2,781  
                                 

Operating expenses:

                                

Research and development

     5,721       708       15,231       2,053  

Sales and marketing

     855       800       2,578       2,141  

General and administrative

     4,696       3,114       16,792       6,277  

Change in estimate of asset retirement obligation

     -       -       (15

)

     -  

Loss on disposal of property and equipment

     -       -       22       -  

Total operating expenses

     11,272       4,622       34,608       10,471  
                                 

Operating loss

     (10,534

)

     (4,208

)

     (33,135

)

     (7,690

)
                                 

Non-operating income (expense):

                                

Interest income

     204       140       872       197  

Interest expense

     (14

)

     -       (60

)

     -  

Other income

     -       -       2       -  

Equity in loss of affiliate

     (12

)

     -       (12

)

     -  

Non-operating income, net

     178       140       802       197  
                                 

Net loss before deferred income tax benefit

     (10,356

)

     (4,068

)

     (32,333

)

     (7,493

)
                                 

Deferred income tax benefit

     -       -       10,500       -  
                                 

Net loss

   $ (10,356

)

   $ (4,068

)

   $ (21,833

)

   $ (7,493

)
                                 

Basic and diluted loss per share

   $ (0.04

)

   $ (0.03

)

   $ (0.08

)

   $ (0.05

)
                                 

Weighted average shares used in computing net loss per share:

                                

Basic and diluted

     280,558       142,072       263,236       142,051  

 

 
 

 

Investor Relations Contact:

LifeSci Advisors

Chuck Padala

E: chuck@lifesciadvisors.com

 

 
 EX-101.SCH 3 isr-20231114.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 isr-20231114_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 isr-20231114_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, Address Line Two Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 isr-20231114_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 ex_597074img001.jpg begin 644 ex_597074img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document And Entity Information
Nov. 14, 2023
Document Information [Line Items]  
Entity, Registrant Name Perspective Therapeutics, Inc.
Document, Type 8-K
Document, Period End Date Nov. 14, 2023
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-33407
Entity, Tax Identification Number 41-1458152
Entity, Address, Address Line One 2401 Elliott Avenue
Entity, Address, Address Line Two Suite 320
Entity, Address, City or Town Seattle
Entity, Address, State or Province WA
Entity, Address, Postal Zip Code 98121
City Area Code 509
Local Phone Number 375-1202
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol CATX
Security Exchange Name NYSEAMER
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0000728387
XML 9 isr20231113_8k_htm.xml IDEA: XBRL DOCUMENT 0000728387 2023-11-14 2023-11-14 false 0000728387 8-K 2023-11-14 Perspective Therapeutics, Inc. DE 001-33407 41-1458152 2401 Elliott Avenue Suite 320 Seattle WA 98121 509 375-1202 false false false false Common Stock CATX NYSEAMER false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.isr.com/20231114/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports isr-20231114.xsd isr-20231114_def.xml isr-20231114_lab.xml isr-20231114_pre.xml isr20231113_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "isr20231113_8k.htm": { "nsprefix": "isr", "nsuri": "http://www.isr.com/20231114", "dts": { "schema": { "local": [ "isr-20231114.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "isr-20231114_def.xml" ] }, "labelLink": { "local": [ "isr-20231114_lab.xml" ] }, "presentationLink": { "local": [ "isr-20231114_pre.xml" ] }, "inline": { "local": [ "isr20231113_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 27, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.isr.com/20231114/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d20238K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "isr20231113_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d20238K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "isr20231113_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.isr.com/20231114/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001437749-23-031996-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-031996-xbrl.zip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